...
首页> 外文期刊>Artificial Organs >Comparison of two platelet activation markers using flow cytometry after in vitro shear stress exposure of whole human blood.
【24h】

Comparison of two platelet activation markers using flow cytometry after in vitro shear stress exposure of whole human blood.

机译:全血体外切应力暴露后使用流式细胞术比较两种血小板活化标志物。

获取原文
获取原文并翻译 | 示例
           

摘要

Platelet activation is the initiating step to thromboembolic complications in blood-contacting medical devices. Currently, there are no widely accepted testing protocols or relevant metrics to assess platelet activation during the in vitro evaluation of new medical devices. In this article, two commonly used platelet activation marker antibodies, CD62P (platelet surface P-selectin) and PAC1 (activated GP IIb/IIIa), were evaluated using flow cytometry. Anticoagulant citrate dextrose solution A (ACDA) and heparin anticoagulated human blood from healthy donors were separately exposed to shear stresses of 0, 10, 15, and 20 Pa for 120 s using a cone-plate rheometer model, and immediately mixed with the platelet marker antibodies for analysis. To monitor for changes in platelet reactivity between donors and over time, blood samples were also evaluated after exposure to 0, 2, and 20 microM of adenosine diphosphate (ADP). Following ADP stimulation, the percentage of both CD62P and PAC1 positive platelets increased in a dose dependent fashion, even 8 h after the blood was collected. After shear stress stimulation, both CD62P and PAC1 positive platelets increased significantly at shear stress levels of 15 and 20 Pa when ACDA was used as the anticoagulant. However, for heparinized blood, the PAC1 positive platelets decreased with increasing shear stress, while the CD62P positive platelets increased. Besides the anticoagulant effect, the platelet staining buffer also impacted PAC1 response, but had little effect on CD62P positive platelets. These data suggest that CD62P is a more reliable marker compared with PAC1 for measuring shear-dependent platelet activation and it has the potential for use during in vitro medical device testing.
机译:血小板活化是接触血液的医疗设备中血栓栓塞并发症的起始步骤。当前,尚没有被广泛接受的测试方案或相关指标来评估新医疗器械的体外评估过程中的血小板活化。在本文中,使用流式细胞仪评估了两种常用的血小板活化标志物抗体CD62P(血小板表面P-选择素)和PAC1(活化的GP IIb / IIIa)。使用锥板流变仪模型分别将来自健康供体的抗凝柠檬酸葡萄糖溶液A(ACDA)和肝素抗凝人体血液分别暴露于0、10、15和20 Pa的剪切应力下120 s,然后立即与血小板标记物混合分析抗体。为了监测供体之间以及随时间的血小板反应性的变化,还对暴露于0、2和20 microM的二磷酸腺苷(ADP)后的血样进行了评估。在ADP刺激后,甚至在采血后8小时,CD62P和PAC1阳性血小板的百分比也呈剂量依赖性增加。剪切应力刺激后,当ACDA用作抗凝剂时,在剪切应力水平为15和20 Pa时,CD62P和PAC1阳性血小板均显着增加。但是,对于肝素化血液,PAC1阳性血小板随切应力的增加而减少,而CD62P阳性血小板则增加。除抗凝作用外,血小板染色缓冲液还影响PAC1反应,但对CD62P阳性血小板影响不大。这些数据表明,与PAC1相比,CD62P是测量剪切依赖性血小板活化的更可靠的标志物,它具有在体外医疗器械测试中使用的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号